• Advocate Spot-on solution for Small Cats
• Advocate Spot-on solution for Large Cats
• Advocate Spot-on solution for Small Dogs
• Advocate Spot-on solution for Medium Dogs
• Advocate Spot-on solution for Large Dogs
• Advocate Spot-on solution for Extra-Large Dogs

Advocate spot-on solution for cats is a clear yellow to brownish solution containing 10 % imidacloprid and 1.0 % moxidectin with benzyl alcohol.

Advocate spot-on solution for dogs is a clear yellow to brownish solution containing 10 % imidacloprid and 2.5 % moxidectin with benzyl alcohol.

The products are presented in a single use plastic tube for cutaneous (spot-on) treatment in cats and dogs.

Each tube of the cat presentations contains either 0.4 ml (40 mg imidacloprid, 4 mg moxidectin) or 0.8 ml (80 mg imidacloprid, 8 mg moxidectin).

Each tube of the dog presentations contains either 0.4 ml (40 mg imidacloprid, 10 mg moxidectin), 1.0 ml (100 mg imidacloprid, 25 mg moxidectin), 2.5 ml (250 mg imidacloprid, 62.5 mg moxidectin) or 4.0 ml (400 mg imidacloprid, 100 mg moxidectin).

For use in cats and dogs suffering from, or at risk from, mixed parasitic infections:

Cats and Dogs: For the treatment and prevention of flea infestation (Ctenocephalides felis), treatment of ear mite infestation (Otodectes cynotis) and prevention of heartworm disease (L3 and L4 larvae of Dirofilaria immitis). The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Cats: For the treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara cati and Ancylostoma tubaeforme).

Dogs: For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis), demodicosis (caused by Demodex canis) and treatment of infections with gastrointestinal nematodes (L4 larvae, immature adults and adults of Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, adults of Toxascaris leonina and Trichuris vulpis).

The recommended minimum doses for cats are 10 mg/kg bodyweight imidacloprid and 1.0 mg/kg bodyweight moxidectin, equivalent to 0.1ml/kg bodyweight Advocate for cats.

The recommended minimum doses for dogs are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1ml/kg bodyweight Advocate for dogs.

The treatment schedule should be based on the local epidemiological situation.

Cats dosage

Dogs dosage

Flea treatment and prevention (Cats & Dogs)

One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine Advocate treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

Treatment of ear mite infestation (Otodectes cynotis) (Cats & Dogs)

A single dose of the product should be administered. In dogs, loose debris should be gently removed from the external ear canal at each treatment. For both cats and dogs, a further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) (Dogs)

A single dose should be administered twice 4 weeks apart.

Treatment of demodicosis (caused by Demodex canis) (Dogs)

A single dose administered 2 to 4 times at 4 weekly intervals is efficacious against Demodex canis and leads to a marked improvement of clinical signs. As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

Heartworm prevention (Cats & Dogs)

Cats and dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with Advocate, the advice provided in Contra-Indications and Warnings etc should be considered.

For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with Advocate must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of animals having heartworm. Therefore they can be treated without special precautions.

Roundworm and hookworm treatment (Cats)

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Roundworm, hookworm and whipworm treatment (Dogs)

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Studies have shown that monthly treatment of dogs will prevent infections caused by Uncinaria stenocephala

The recommended minimum doses for cats are 10 mg/kg bodyweight imidacloprid and 1.0 mg/kg bodyweight moxidectin, equivalent to 0.1ml/kg bodyweight Advocate for cats.
 

The recommended minimum doses for dogs are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1ml/kg bodyweight Advocate for dogs.
 

The treatment schedule should be based on the local epidemiological situation.
 

Cats 

Dogs

Flea treatment and prevention (Cats & Dogs)

One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine Advocate treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.

Treatment of ear mite infestation (Otodectes cynotis) (Cats & Dogs)

 A single dose of the product should be administered. In dogs, loose debris should be gently removed from the external ear canal at each treatment. For both cats and dogs, a further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.

Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) (Dogs)

A single dose should be administered twice 4 weeks apart.

Treatment of demodicosis (caused by Demodex canis) (Dogs)

A single dose administered 2 to 4 times at 4 weekly intervals is efficacious against Demodex canis and leads to a marked improvement of clinical signs. As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

Heartworm prevention (Cats & Dogs)

Cats and dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with Advocate, the advice provided in Contra-Indications and Warnings etc should be considered.

For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit heartworm larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with Advocate must be given within 1 month of the last dose of the former medication.

In non-endemic areas there should be no risk of animals having heartworm. Therefore they can be treated without special precautions.

Roundworm and hookworm treatment (Cats)

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Roundworm, hookworm and whipworm treatment (Dogs)

In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.

Studies have shown that monthly treatment of dogs will prevent infections caused by Uncinaria stenocephala

Method of administration

For external use only.

Remove one pipette from the package. Then hold the pipette in an upright position, and twist and pull off the cap. Reverse the cap and use it to twist and remove the seal from the pipette.

Cats:

Part the fur on the cat's neck at the base of the skull until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin. Application at the base of the skull will minimise the opportunity for the cat to lick the product. Apply only to undamaged skin.

For dogs up to 25 kg:

With the dog in a standing position, part the coat between the shoulder blades until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin.

For dogs of more than 25 kg:

For easy application the dog should be standing. The entire contents of the pipette should be applied evenly as 3 or 4 spots along the top of the back, from between the shoulders to the base of the tail. At each spot, part the coat until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly onto the skin. Do not apply an excessive amount of solution at any one spot, as that could cause some of the product to run down the animal’s side.

Warnings 

• Do not use in kittens under 9 weeks of age.
• Do not use in puppies under 7 weeks of age.
• Treatment of animals weighing less than 1 kg should be based on a risk-benefit assessment.
• There is limited experience on the use of the product in sick and debilitated animals, thus the product should only be used based on a risk-benefit assessment for these animals.
• For cats, ‘Advocate Spot-on Solution for cats’, which contains 10 % imidacloprid and 1.0 % moxidectin, must be used.
• For dogs, the ‘Advocate Spot-on Solution for dogs’, which contains 10 % imidacloprid and 2.5 % moxidectin, must be used.
• Use of the product may result in transient pruritus in the animal. On rare occasions greasy fur, erythema and vomiting can occur. These signs disappear without further treatment. If the animal licks the application site after treatment, transient neurological signs may be observed infrequently.
• The product tastes bitter. Salivation may occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application site.
• Care should be taken that the contents of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/or other animals. Do not allow recently treated animals to groom each other. When the product is applied in 3 to 4 separate spots in larger dogs, specific care should be taken to prevent the animal licking the application sites.
• As with any product containing macrocyclic lactones, special care should be taken with Collies, Old English Sheepdogs and related breeds or crossbreeds, to correctly administer the product as described above. In particular, oral uptake by the recipient and/or other animals should be prevented.
• Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms: moxidectin is highly toxic to aquatic organisms. Dogs should not be allowed to swim in surface waters for 4 days after treatment.
• It is recommended that cats living in, or travelling to areas endemic for heartworm are treated monthly with the product to protect them from heartworm disease. Whilst the accuracy of diagnosis of feline heartworm infection is limited, it is recommended that attempts be made to check the heartworm status of any cat aged over 6 months, before beginning prophylactic treatment, as use of the product on cats which have adult heartworms may cause serious adverse effects, including death. If adult heartworm infection is diagnosed, the infection should be treated in accordance with current scientific knowledge.
• Although the product may be safely administered to dogs infected with adult heartworms, it has no therapeutic effect against adult Dirofilaria immitis. It is therefore recommended that all dogs 6 months of age or more, living in areas endemic for heartworm, should be tested for existing adult heartworm infection before being treated with the product.
• The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Laboratory studies with either imidacloprid or moxidectin in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. Use only according to the risk-benefit assessment.
• During treatment with Advocate no other antiparasitic macrocyclic lactone should be administered.
• No interactions between Advocate and routinely used veterinary medicinal products or medical or surgical procedures have been observed.
• Up to 10 times the recommended dose was tolerated in adult and dogs cats with no evidence of adverse effects or undesirable clinical signs.
• The product was administered to kittens and puppies at up to 5 times the recommended dose, every 2 weeks for 6 treatments, and there were no serious safety concerns. Transient mydriasis, salivation, vomiting and transient rapid respiration were observed.
• After accidental oral ingestion, transient neurological signs such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur infrequently.
• In case of accidental oral uptake, symptomatic treatment should be administered. There is no known specific antidote. The use of activated charcoal may be beneficial.
• Ivermectin-sensitive Collie dogs tolerated up to 5 times the recommended dose without any adverse effects. However, when 40% of the unit dose was given orally, severe neurological signs were observed. Oral administration of 10% of the recommended dose produced no adverse effects.
• Dogs infected with adult heartworms tolerated up to 5 times the recommended dose, every 2 weeks for 3 treatments, without any adverse effects.
• Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the product.
• Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

User Safety

• Avoid contact with skin, eyes or mouth.
• Do not eat, drink or smoke during application.
• Wash hands thoroughly after use.
• After application do not stroke or groom animals until the application site is dry.
• In case of accidental spillage onto skin, wash off immediately with soap and water.
• People with a known hypersensitivity to either benzyl alcohol, imidacloprid or moxidectin should administer the product with caution. In very rare cases the product may cause skin sensitisation or transient skin reactions (for example allergy, irritation or tingling).
• If the product accidentally gets into eyes, they should be thoroughly flushed with water.
• If skin or eye symptoms persist, or the product is accidentally swallowed, seek medical attention and show the package insert to the physician.

Environmental Safety 

• Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
• Advocate should not be allowed to enter surface waters as it has harmful effects on aquatic organisms.

Do not store above 30º C.

Legal Category: POM

Imidacloprid, 1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamine is an ectoparasiticide belonging to the chloronicotinyl group of compounds. Chemically, it is more accurately described as a chloronicotinyl nitroguanidine. Imidacloprid is effective against larval flea stages and adult fleas. Flea larvae in the pet’s surroundings are killed after contact with a pet treated with the product. Imidacloprid has a high affinity for the nicotinergic acetylcholine receptors in the post-synaptic region of the central nervous system (CNS) of the flea. The ensuing inhibition of cholinergic transmission in insects results in paralysis and death. Due to the weak nature of the interaction with mammalian nicotinergic receptors and the postulated poor penetration through the blood-brain barrier in mammals, it has virtually no effect on the mammalian CNS. Imidacloprid has minimal pharmacological activity in mammals.

Moxidectin, 23-(O-methyloxime)-F28249 alpha is a second-generation macrocyclic lactone of the milbemycin family. It is a parasiticide which is active against many internal and external parasites. Moxidectin is active against larval stages (L3, L4) of Dirofilaria immitis. It is also active against gastrointestinal nematodes. Moxidectin interacts with GABA and glutamate-gated chloride channels. This leads to opening of the chloride channels on the postsynaptic junction, the inflow of chloride ions and induction of an irreversible resting state. The result is flaccid paralysis of affected parasites, followed by their death and/or expulsion.

After topical administration of the product, imidacloprid is rapidly distributed over the animal’s skin within one day of application. It can be found on the body surface throughout the treatment interval. Moxidectin is absorbed through the skin, reaching maximum plasma concentrations approximately 1 to 2 days after treatment in cats. Following absorption from the skin, moxidectin is distributed systemically and is slowly eliminated from the plasma as manifested by detectable moxidectin concentrations in plasma throughout the treatment interval of one month.

The solvent in Advocate may stain certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

This site has been created by www.MedicAnimal.com for information purposes only. MedicAnimal is a proud retailer of Advocate but is not affiliated with or related to the manufacturer of Advocate and the contents of this site are neither sponsored or endorsed by the manufacturer of Advocate.